{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:26:24Z","timestamp":1770506784051,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,7,3]],"date-time":"2010-07-03T00:00:00Z","timestamp":1278115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00280-010-1389-7","type":"journal-article","created":{"date-parts":[[2010,7,2]],"date-time":"2010-07-02T04:15:06Z","timestamp":1278044106000},"page":"927-933","source":"Crossref","is-referenced-by-count":22,"title":["A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer"],"prefix":"10.1007","volume":"67","author":[{"given":"Srikala S.","family":"Sridhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M.","family":"Canil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien J.","family":"Hotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Juhasz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Zwiebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,3]]},"reference":[{"key":"1389_CR1","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/1078-0432.CCR-07-0944","volume":"14","author":"DR Berthold","year":"2008","unstructured":"Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI (2008) Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14:2763\u20132767","journal-title":"Clin Cancer Res"},{"key":"1389_CR2","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1021\/bi00475a007","volume":"29","author":"S Bjorklund","year":"1990","unstructured":"Bjorklund S, Skog S, Tribukait B, Thelander L (1990) S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs. Biochemistry 29:5452\u20135458","journal-title":"Biochemistry"},{"key":"1389_CR3","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","volume":"17","author":"GJ Bubley","year":"1999","unstructured":"Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461\u20133467","journal-title":"J Clin Oncol"},{"key":"1389_CR4","doi-asserted-by":"crossref","unstructured":"Buch-Hansen TZ, Bentzen L, Hansen S, Hoeyer M, Jensen NV, Saxe C, Sengeloev L (2009) Phase I\/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. Cancer Chemother Pharmacol","DOI":"10.1007\/s00280-009-1163-x"},{"key":"1389_CR5","first-page":"2301","volume":"26","author":"A Cricca","year":"2006","unstructured":"Cricca A, Marino A, Valenti D, Melotti B, Amaducci E, Guardigli C, Lenzi M, Martorana G, Buli P, Martoni AA (2006) Gemcitabine plus mitoxantrone and prednisone in the palliative treatment of hormone-resistant prostate cancer (HRPC): a phase II study (GOAM 01.01 study). Anticancer Res 26:2301\u20132306","journal-title":"Anticancer Res"},{"key":"1389_CR6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdi178","volume":"16","author":"AA Desai","year":"2005","unstructured":"Desai AA, Schilsky RL, Young A, Janisch L, Stadler WM, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ (2005) A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 16:958\u2013965","journal-title":"Ann Oncol"},{"key":"1389_CR7","first-page":"1650","volume":"58","author":"H Fan","year":"1998","unstructured":"Fan H, Villegas C, Huang A, Wright JA (1998) The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 58:1650\u20131653","journal-title":"Cancer Res"},{"key":"1389_CR8","first-page":"4876","volume":"57","author":"A Huang","year":"1997","unstructured":"Huang A, Fan H, Taylor WR, Wright JA (1997) Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability. Cancer Res 57:4876\u20134881","journal-title":"Cancer Res"},{"key":"1389_CR9","first-page":"1299","volume":"15","author":"A Juhasz","year":"2006","unstructured":"Juhasz A, Vassilakos A, Chew HK, Gandara D, Yen Y (2006) Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep 15:1299\u20131304","journal-title":"Oncol Rep"},{"key":"1389_CR10","doi-asserted-by":"crossref","unstructured":"Kelly W, Halabi S, Carducci M, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff P, Monk JP, Small EJ (2010) A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol, Annu Meet Proc: Abstract No. LBA4511","DOI":"10.1200\/jco.2010.28.18_suppl.lba4511"},{"key":"1389_CR11","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1158\/1078-0432.CCR-08-0109","volume":"14","author":"RB Klisovic","year":"2008","unstructured":"Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G (2008) Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res 14:3889\u20133895","journal-title":"Clin Cancer Res"},{"key":"1389_CR12","unstructured":"Klisovic RB, Blum W, X W, S L, C K, L H, Zwiebel JA, Byrd JC, Grever MR, Marcucci G (2009) A phase 1 study of GTI-2040, an antisense to ribonucleotide reductase (RNR) in combination with high dose cytarabine (HiDAC) in relapsed or refractory acute myeloid leukemia (AML): pharmacokinetics (PK), pharmacodynamic (PD) and clinical results. Blood (Ash Annu Meet Abstr) 106"},{"key":"1389_CR13","unstructured":"Lee Y, Avolino T, Feng N, Xiong K, Jin H, Wang M, Wright J, Young A (2007) Determination of optimized administration schedule of GTI-2040 and docetaxel combination treatment for NSCLC cells in vitro and in vivo. In: Proceedings of the American Association of Cancer Research Annual Meeting"},{"key":"1389_CR14","first-page":"2802","volume":"63","author":"Y Lee","year":"2003","unstructured":"Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J, Young A (2003) GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 63:2802\u20132811","journal-title":"Cancer Res"},{"key":"1389_CR15","doi-asserted-by":"crossref","unstructured":"Leighl NB, Laurie SA, Knox JJ, Ellis PM, Shepherd FA, Burkes RL, Vincent M, Pond GR, Zwiebel JA, Moore MJ (2005) Phase I\/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol, Annu Meet Proc: Abstract No. 7253","DOI":"10.1200\/jco.2005.23.16_suppl.7253"},{"key":"1389_CR16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008332724977","volume":"11","author":"R Morant","year":"2000","unstructured":"Morant R, Bernhard J, Maibach R, Borner M, Fey MF, Thurlimann B, Jacky E, Trinkler F, Bauer J, Zulian G, Hanselmann S, Hurny C, Hering F (2000) Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 11:183\u2013188","journal-title":"Ann Oncol"},{"key":"1389_CR17","first-page":"1462","volume":"2","author":"RM Orr","year":"2001","unstructured":"Orr RM (2001) GTI-2040. Lorus therapeutics. Curr Opin Investig Drugs 2:1462\u20131466","journal-title":"Curr Opin Investig Drugs"},{"key":"1389_CR18","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513\u20131520","journal-title":"N Engl J Med"},{"key":"1389_CR19","doi-asserted-by":"crossref","unstructured":"Scher H, Chi KN, De Wit R, Berry WR, Albers P, Henick B, Venner P, Heidenreich A, Chu L, Heller G (2010) Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): results from Phase III ASCENT2 trial. J Clin Oncol, Annu Meet Proc: Abstract No. 4509","DOI":"10.1200\/jco.2010.28.15_suppl.4509"},{"key":"1389_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"1389_CR21","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512","journal-title":"N Engl J Med"},{"key":"1389_CR22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1389_CR23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jchromb.2005.09.036","volume":"829","author":"W Zhang","year":"2005","unstructured":"Zhang W, Leighl N, Zawisza D, Moore MJ, Chen EX (2005) Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions. J Chromatogr B Analyt Technol Biomed Life Sci 829:45\u201349","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1389-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1389-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1389-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T13:24:26Z","timestamp":1559222666000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1389-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,3]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["1389"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1389-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,3]]}}}